% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

  • michaelplongo michaelplongo Mar 13, 2013 7:15 PM Flag

    Edison Investment Research raises price target

    I just viewed a 16 page research report on ASTX dated March 11. Pretty good info with competitors and their progress listed. It starts out:
    Astex’s investment case has advanced considerably in recent months with its significant expansion of studies with its second-generation hypomethylating agent SGI-110, and it Hsp90 inhibitor AT13387. Astex now has six Phase I/II studies underway with these two focus products and should present final results from the first – a Phase I/II study of SGI-110 in MDS/AML – at ASH. We have revised our valuation to reflect these developments and now indicate a value of $599m, equivalent to $6.42/share basic or $5.50/diluted share.

    SortNewest  |  Oldest  |  Most Replied Expand all replies